Compare · BDX vs EW
BDX vs EW
Side-by-side comparison of Becton Dickinson and Company (BDX) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BDX focuses on Medical/Dental Instruments, while EW focuses on Industrial Specialties.
- EW is the larger of the two at $48.42B, about 1.1x BDX ($42.51B).
- Over the past year, BDX is down 11.5% and EW is up 11.0% - EW leads by 22.5 points.
- BDX has been more active in the news (15 items in the past 4 weeks vs 6 for EW).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Edwards Lifesciences Corporation
- Price
- $149.44+0.23%
- $83.99+0.54%
- Market cap
- $42.51B
- $48.42B
- 1M return
- -4.40%
- +3.30%
- 1Y return
- -11.46%
- +11.04%
- Industry
- Medical/Dental Instruments
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 15
- 6
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest BDX
- BD Achieves Excellence in Employee Well‑Being, Earning Top Industry Recognition
- Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,244 worth of shares (74 units at $151.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,159 units (SEC Form 4)
- BD to Present at Bank of America Securities Health Care Conference
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
Latest EW
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation